Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Sco ...

A month has gone by since the last earnings report for Corcept Therapeutics (CORT) . Shares have added about 19.7% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Corcept due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Corcept Beats Q3 Earnings & Sales Estimates, ...

Welcome to my profile!My name is Vincent. I have over three years of experience as a tech-oriented buy-side analyst at a major bank, where I co-managed U.S. equity portfolios with over $700M in assets under management. I’ve worked across both large-cap and small-cap stocks, gaining a deep understanding of financial markets. Fascinated by innovation and its potential, my goal is not only to identify tomorrow's future leaders but also to share and discuss these insights with you.I believe every investor shoul ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Za ...

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Gro ...

Corcept Therapeutics (CORT) closed the last trading session at $54.31, gaining 11% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $74.90 indicates a 37.9% upside potential.The mean estimate comprises five short-term price targets with a standard deviation of $5.03. While the lowest estimate of $67 indicates a 23.4% increase from the current price level, the most optimistic analyst ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the st ...

Industry Overview - The drug industry is anticipating a shift in policy with Donald Trump's reelection, potentially leading to increased innovation and M&A activity, while efforts to repeal the Inflation Reduction Act (IRA) are likely [1][2] - Drug pricing reforms will remain a priority for the new government, with previous emphasis on controlling drug prices during Trump's last term [2] - The Zacks Medical-Drugs industry is showing promising trends in 2024, driven by increased M&A and positive pipeline developments, particularly in diabetes/obesity, inflammation, and neuroscience [3] Company Highlights - **Corcept Therapeutics**: The company’s sole marketed drug, Korlym, has seen strong demand, leading to an increase in annual revenue guidance. The stock has risen 67.2% this year, with 2024 earnings estimates increasing from $1.12 to $1.31 per share [15][16] - **Madrigal Pharmaceuticals**: The FDA approved Rezdiffra, the first therapy for noncirrhotic NASH, generating approximately $77 million in sales since its launch. The stock is up 53.4% this year, with loss estimates improving from $29.49 to $24.08 per share [17][18] - **Catalyst Pharmaceuticals**: The lead drug Firdapse is experiencing strong demand, and the company has diversified its portfolio with the acquisition of Fycompa. The stock has risen 38.3% this year, with stable earnings estimates at $1.92 per share [19][20] - **Theravance Biopharma**: The company is benefiting from increased collaboration revenues from its product Yupelri. However, the stock has declined 22.1% this year, with stable loss estimates at 45 cents per share [21][23] - **Larimar Therapeutics**: The company is developing nomlabofusp for Friedreich's ataxia, with a significant stock increase of 100.5% over the past year. Loss estimates have narrowed from $1.39 to $1.16 per share [24][26] Market Performance - The Zacks Medical-Drugs industry has underperformed the S&P 500 and the broader Medical sector, with a year-to-date decline of 3.4% compared to the S&P 500's increase of 24.7% [13] - The industry currently trades at a price-to-sales ratio of 2.24, significantly lower than the S&P 500's 6.19 and the Zacks Medical sector's 3.44 [14]

The drug industry witnessed major policy changes during Joe Biden's four-year term as U.S. President, including the historic Inflation Reduction Act (“IRA”). With Donald Trump’s reelection, the biotech industry hopes to witness more innovation and mergers and acquisitions (M&A) activity. Efforts to repeal the IRA look likely. However, it all depends on who is appointed to key roles at federal health agencies. Drug pricing reforms are expected to remain a key priority for the new government. Trump, in his pr ...

Corcept Therapeutics Incorporated (CORT) has been having a fabulous 2024, with its share price increasing 60.5% year to date as of Nov. 5, 2024.This company engages in the discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic and neurologic disorders in the United States. It has spent more than 25 years dedicated to advancing cortisol modulation, resulting in the discovery of more than 1,000 unique selective modulators. Remaining focused on innovation, Corcept i ...